Christopher R. Leland

Christopher R. Leland

Auto-generated profile, based on publicly available information

Christopher R. Leland

Harvard Medical School Orthopaedic Trauma Initiative, Boston, MA, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 July 2022 in Clinical Orthopaedics and Related Research
Verified
Journal Article
Closed access
DBDaniel Badin
Daniel Badin
COCarlos D. Bs Ortiz-Babilonia
Carlos D. Bs Ortiz-Babilonia
AGArjun Bs Gupta
Arjun Bs Gupta
CLChristopher R. Bs Leland
Christopher R. Bs Leland
FMFarah Musharbash
Farah Musharbash
AAAmiethab A. Aiyer
Amiethab A. Aiyer
Background: Pain management after foot and ankle surgery must surmount unique challenges that are not present in orthopaedic surgery performed on other parts of the body. However, disparate and inconsistent evidence makes it difficult to draw meaningful conclusions from individual studies. Questions/purposes: In this systematic review, we asked: what are (1) the patterns of opioid use or prescription (quantity, duration, incidence of persistent use), (2) factors associated with increased or decreased risk of persistent opioid use, and (3) the clinical outcomes (principally pain relief and adverse events) associated with opioid use in patients undergoing foot or ankle fracture surgery? Methods: We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines for our review. We searched PubMed, Embase, Scopus, Cochrane, and Web of Science on October 15, 2021. We included studies published from 2010 to 2021 that assessed patterns of opioid use, factors associated with increased or decreased opioid use, and other outcomes associated with opioid use after foot or ankle fracture surgery (principally pain relief and adverse events). We excluded studies on pediatric populations and studies focused on acute postoperative pain where short-term opioid use (< 1 week) was a secondary outcome only. A total of 1713 articles were assessed and 18 were included. The quality of the 16 included retrospective observational studies and two randomized trials was evaluated using the Methodological Index for Non-Randomized Studies criteria and the Jadad scale, respectively; study quality was determined to be low to moderate for observational studies and good for randomized trials. Mean patient age ranged from 42 to 53 years. Fractures studied included unimalleolar, bimalleolar, trimalleolar, and pilon fractures. Results: Proportions of postoperative persistent opioid use (defined as use beyond 3 or 6 months postoperatively) ranged from 2.6% (546 of 20,992) to 18.5% (32 of 173) and reached 39% (28 of 72) when including patients with prior opioid use. Among the numerous associations reported by observational studies, two or more preoperative opioid prescriptions had the strongest overall association with increased opioid use, but this was assessed by only one study (OR 11.92 [95% confidence interval (CI) 9.16 to 13.30]; p < 0.001). Meanwhile, spinal and regional anesthesia (-13.5 to -41.1 oral morphine equivalents (OME) difference; all p < 0.01) and postoperative ketorolac use (40 OME difference; p = 0.037) were associated with decreased opioid consumption in two observational studies and a randomized trial, respectively. Three observational studies found that opioid use preoperatively was associated with a higher proportion of emergency department visits and readmission (OR 1.41 to 17.4; all p < 0.001), and opioid use at 2 weeks postoperatively was associated with slightly higher pain scores compared with nonopioid regimens (β = 0.042; p < 0.001 and Likert scale 2.5 versus 1.6; p < 0.05) in one study. Conclusion: Even after noting possible inflation of the harms of opioids in this review, our findings nonetheless highlight the need for opioid prescription guidelines specific for foot and ankle surgery. In this context, surgeons should utilize short (< 1 week) opioid prescriptions, regional anesthesia, and multimodal pain management techniques, especially in patients at increased risk of prolonged opioid use. Level of Evidence: Level III, therapeutic study.

30 January 2024 in Foot & Ankle Orthopaedics
Verified
Journal Article
Open access
AOArinze Ochuba
Arinze Ochuba
CMChristopher J. Murdock
Christopher J. Murdock
AXAmy L. Xu
Amy L. Xu
MSMorgan Snow
Morgan Snow
JSJessica Schmerler
Jessica Schmerler
AAAmiethab A. Aiyer
Amiethab A. Aiyer
Background: Lisfranc fracture-dislocation is an uncommon but serious injury that currently lacks universal consensus on optimal operative treatment. Two common fixation methods are open reduction and internal fixation (ORIF) and primary arthrodesis (PA). The objective of this study is to analyze the cost difference between ORIF and PA of Lisfranc injuries, along with the contribution of medical services to overall costs. Methods: This was a retrospective cost analysis of the MarketScan database from 2010 to 2020. MarketScan is an insurance and commercial claims database that integrates deidentified patient information. It captures person-specific clinical utilization, expenditures, and enrollment across inpatient and outpatient services. Patients undergoing primary ORIF ( CPT code 28615) vs PA (28730 and 28740) for Lisfranc fracture-dislocation were identified. The primary independent variable was ORIF vs PA of Lisfranc injury. Total costs due to operative management was the primary objective. The utilization of and costs contributed by medical services was a secondary outcome. Results: From 2010 to 2020, a total of 7268 patients underwent operative management of Lisfranc injuries, with 5689 (78.3%) ORIF and 1579 (21.7%) PA. PA was independently associated with increased net and total payment and coinsurance, clinic visits, and imaging, and patients attended significantly more PT sessions. Conclusion: Using this large database that does not characterize severity or extent of injury, we found that treatment of Lisfranc fracture-dislocation with ORIF was associated with substantially lower initial episode of treatment costs compared with PA. Specific excessive cost drivers for PA were clinic visits, PT sessions, and imaging. Level of Evidence: Level III, retrospective cohort study.

3 October 2022 in JBJS Open Access
Verified
Journal Article
Open access
RMRidge Maxson
Ridge Maxson
MGMiriyam Ghali
Miriyam Ghali
CLChristopher R. Leland
Christopher R. Leland
GTGregory R. Toci
Gregory R. Toci
CMClaire McDaniel
Claire McDaniel
AAAmiethab A. Aiyer
Amiethab A. Aiyer
Background: The purpose of this study was to assess the influence of the COVID-19 pandemic on the 2021 orthopaedic surgery residency match outcomes. Because in-person away rotations and interviews were canceled during the 2020 to 2021 application cycle, we hypothesized that applicants would match at their home program at a higher rate in 2021 than in previous years. Methods: We queried allopathic orthopaedic surgery residency websites and social media accounts for names of residents and medical school information for cohorts matching from 2017 through 2021. To assess availability of and participation in virtual away rotations, we administered a survey to Accreditation Council for Graduate Medical Education–accredited allopathic orthopaedic surgery residency programs. The primary outcome was the annual proportion of applicants matching at the program affiliated with their medical school (“home program”). Subgroup analyses were stratified by Doximity reputation ranking and availability of a virtual away rotation. Results: We identified 2,632 residents who matched between 2017 and 2020 and 698 residents who matched in 2021. Overall home program match rate and likelihood of home matching were higher in 2021 compared with 2017 to 2020 (28% vs. 20%; odds ratio [OR] = 1.51, 95% confidence interval [CI] 1.24-1.82, p < 0.001). The increase in the home match rate at programs ranked in the top 30 (27% vs. 20%, p = 0.034) was similar to the increase at programs ranked outside the top 30 (28% vs. 20%, p < 0.001). Of the 66 (48%) programs that responded to the survey, 16 (24%) offered a virtual away rotation. Programs with a higher Doximity ranking were more likely than lower-ranked programs to offer a virtual away rotation (OR = 6.75, 95% CI 1.95-23.4, p = 0.003). Home match rates did not differ significantly between programs that offered a virtual away rotation and those that did not (26% vs. 32%, p = 0.271). Conclusions: A higher proportion of orthopaedic surgery residency applicants matched at their home program in 2021 compared with previous years. Limitations on in-person activities due to the COVID-19 pandemic may have contributed to this rise. Level of Evidence: N/A.

22 October 2024 in Clinical Orthopaedics and Related Research
Verified
Journal Article
Closed access
CLChristopher R. Leland
Christopher R. Leland
MGMarcos Roberto Gonzalez
Marcos Roberto Gonzalez
JWJoseph O. Bs Werenski
Joseph O. Bs Werenski
AVAnthony T. Bs Vallone
Anthony T. Bs Vallone
KBKirsten G. Bs Brighton
Kirsten G. Bs Brighton
KRKevin A. Raskin
Kevin A. Raskin
Background: Limiting reoperation or revision after operative stabilization or endoprosthetic reconstruction of a pathologic subtrochanteric femur fracture reduces morbidity, but how best to achieve this remains controversial. Endoprosthetic reconstruction offers durable mechanical stability but may not be most appropriate in patients who are frail or who are not expected to survive more than a few months. For that reason, cumulative incidence survival (looking at the endpoint of reoperation or revision with death as a competing risk) and factors associated with revision after surgical stabilization or reconstruction—both of which remain poorly characterized to date—would help surgeons make better decisions on behalf of these patients. Questions/purposes: We analyzed patients who were operatively treated for pathologic subtrochanteric femur fracture, and we asked: (1) What is the cumulative incidence of reoperation and revision at 3 months, 1 year, and 2 years after surgery for pathologic subtrochanteric femur fracture in patients undergoing each treatment type with death as a competing risk? (2) What are the factors associated with implant revision after operative treatment of pathologic subtrochanteric femur fracture? (3) What is the overall survival of patients in this population after surgery? (4) How do clinical and surgical factors along with the frequency of complications compare in this population by operative treatment? Methods: Between January 2000 and December 2020, 422 patients underwent surgery for completed proximal femur pathologic fractures. After excluding patients with non-subtrochanteric femur fractures (71% [301]), fractures caused by primary tumors of bone (< 1% [2]), and insufficient data (1% [6]), we included 113 patients who underwent operative treatment of completed pathologic subtrochanteric femur fractures. Our study period spanned 20 years because although implant trends may have shifted, the overall operative objective for pathologic subtrochanteric femur fractures—restoring function and alleviating pain, regardless of the extent of bony union—have remained relatively unchanged during this period. Median follow-up time was 6 months (range 1 month to 20.6 years). Intramedullary nailing (IMN) was performed in 68% (77) of patients, proximal femur replacement (PFR) was performed in 19% (22), and open reduction and internal fixation (ORIF) was performed in 12% (14) of patients. IMN was performed in patients with a poor prognosis but in whom fracture stabilization was felt to be advantageous. In instances of complex fractures in which adequate reduction could not be achieved, ORIF was generally performed. PFR was generally performed in patients with a better prognosis in which long-term implant survival and patient function were prioritized. We found a higher proportion of women in the IMN group (73% versus 32% in PFR and 50% in ORIF; p = 0.001). Rapid growth tumors (Katagiri classification) were found in 25% of patients with IMN, 27% with PFR, and 43% with ORIF. The primary outcome was the cumulative incidence of reoperation or revision surgery after initial stabilization. Competing risk analysis with death as a competing event was performed to estimate the cumulative incidence for reoperation and revision. Factors associated with revision surgery were identified using the Cox proportional hazards model, which rendered HRs. All analyses were adjusted to control for potential confounders. Results: The cumulative incidence for reoperation at 2 years was 5% (95% confidence interval [CI] 4% to 6%) for IMN, 15% (95% CI 9% to 22%) for PFR, and 32% (95% CI 15% to 50%) for ORIF (p = 0.03). The cumulative incidence for revision at 2 years was 4% (95% CI 3% to 4%) for IMN, 4% (95% CI 2% to 6%) for PFR, and 33% (95% CI 15% to 51%) for ORIF (p = 0.01). Factors associated with revision surgery were radioresistant tumor histology (HR 8.5 [95% CI 1.2 to 58.9]; p = 0.03) and ORIF (HR 6.3 [95% CI 1.5 to 27.0]; p = 0.01). The 3-month, 1-year, and 2-year overall survival was 80% (95% CI 71% to 87%), 35% (95% CI 26% to 45%), and 28% (95% CI 19% to 36%), respectively. Thirty-day postoperative complications did not differ by fixation type, but 90-day readmission was highest after ORIF (3 of 14 versus 4 of 22 in PFR and 4% [3 of 77] in IMN; p = 0.03) Periprosthetic joint infection (PJI) was more common after salvage PFR (2 of 6) than primary PFR (1 of 22) (p = 0.04). Conclusion: Primary PFR may be preferred for pathologic subtrochanteric femur fractures arising from radioresistant tumor types, as the cumulative incidence of revision was no different than for IMN while restoring function, alleviating pain, and offering local tumor control, and it less commonly develops PJI than salvage PFR. In complex fractures not amenable to IMN, surgeons should consider performing a PFR over ORIF because of the lower risk of revision and the added benefit of replacing the pathologic fracture altogether and offering immediate mechanical stability with a cemented endoprosthesis. Future studies might evaluate the extent of bone loss from local tumor burden, and this could be quantified and analyzed in future studies as a covariate as it may clarify when PFR is advantageous in this population. Level of Evidence: Level III, therapeutic study.

1 January 2023 in JBJS Case Connector
Verified
Journal Article
Closed access
CLChristopher R. Leland
Christopher R. Leland
CPChristine A. Pratilas
Christine A. Pratilas
JGJohn M. Gross
John M. Gross
ALAdam S. Levin
Adam S. Levin
Case: We present a 23-year-old man with acute-on-chronic shoulder pain with an aggressive-appearing, destructive lesion of the left proximal humerus and diffuse lung metastases. Biopsy revealed conventional giant cell tumor of bone (GCTB) without sarcomatous differentiation, treated with resection and proximal humerus reconstruction. Without systemic treatment, his pulmonary metastases demonstrated modest spontaneous regression, with no impairment of pulmonary function. Conclusions: Although GCTB is known to metastasize to lungs, these deposits most commonly follow local recurrence. We describe a young adult with diffuse pulmonary nodules at initial presentation, although still following an indolent clinical course without the need for additional systemic therapy.

16 August 2023 in Journal of Orthopaedics
Verified
Journal Article
Closed access
CLChristopher R. Leland
Christopher R. Leland
CMCarol D. Morris
Carol D. Morris
JFJonathan A. Forsberg
Jonathan A. Forsberg
ALAdam S. Levin
Adam S. Levin